Triple vaccine protects against bacterial and fungal pathogens via trained immunity
An optimized protein-free tripartite vaccine that protects against lethal blood and lung infections caused by a variety of nosocomial pathogens across taxonomic kingdoms, including Gram-positive bacteria, Gram-negative bacteria, and fungi.
1. A method of enhancing innate immunity against an infection caused by a bacterial pathogen or a fungal pathogen in a mammalian subject in need thereof, the method comprising administering to the subject an effective amount of a combination
immunostimulatory composition comprising an effective amount of each of monophosphoryl lipid A (MPL), mannan, and aluminum hydroxide, with the proviso that the composition does not comprise whole glucan particles (WGP) and an antigen that is effective to induce an immune response against the bacterial pathogen or the fungal pathogen.
2. The method of claim 1 , wherein the bacterial pathogen is Staphylococcus aureus, Acinetobacter baumannii, Klebsiella pneumoniae, Pseudomonas aeruginosa , and Enterococcus faecalis , and wherein the fungal pathogen is Candida albicans or Rhizopus delemar.
3. The method of claim 1 , wherein the composition is administered by inhalation, intramuscular, subcutaneous, or intravenous administration.
4. The method of claim 1 , wherein the composition is administered once, twice, or three times over a period of one to three months.
5. The method of claim 1 , wherein the mammalian subject is at risk of the infection caused by the bacterial pathogen or the fungal pathogen, or wherein the subject is infected with the bacterial pathogen or the fungal pathogen.
6. The method of claim 1 , further comprising assaying a sample from the mammalian subject for infection with the bacterial pathogen or the fungal pathogen.
7. The method of claim 1 , wherein the immune response is an adaptive immune response mediated by T-cell and/or B-cell lymphocytes against the bacterial pathogen or the fungal pathogen.
8. The method of claim 1 , wherein the effective amount of each of the aluminum hydroxide, the MPL, and the mannan is collectively effective to enhance the innate immunity to the bacterial pathogen or to the fungal pathogen in the mammalian subject.
9. The method of claim 1 , wherein the antigen is selected from a peptide, a protein, or a glycoprotein.
10. The method of claim 1 , wherein the aluminum hydroxide is an aluminum hydroxide wet suspension, optionally a 2% aluminum hydroxide wet suspension, or a 1% aluminum hydroxide wet suspension.
11. The method of claim 1 , wherein the effective amount comprises:
(a) from about 0.1 mg/ml to about 10 mg/ml of the aluminum hydroxide;
(b) from about 0.1 mg/ml to about 10 mg/ml of the MPL; and
(c) from about 0.1 mg/ml to about 10 mg/ml of the mannan.
12. The method of claim 1 , further comprising a pharmaceutically acceptable carrier, optionally saline or phosphate buffered saline.
13. The method of claim 1 , wherein the effective amount of each of the aluminum hydroxide, the MPL, and the mannan collectively does not induce antibodies specific to the bacterial pathogen or to the fungal pathogen in the subject.
14. The method of claim 1 , wherein the mammalian subject is immunocompromised or neutropenic.
15. A method of enhancing innate immunity against an infection caused by a bacterial pathogen or a fungal pathogen in a mammalian subject in need thereof, the method comprising administering to the subject an effective amount of a combination immunostimulatory composition consisting essentially of an effective amount of each of monophosphoryl lipid A (MPL), mannan, and aluminum hydroxide, with the proviso that the composition does not comprise whole glucan particles (WGP) and an antigen that is effective to induce an immune response against the bacterial pathogen or the fungal pathogen.